FindTrial
Sign In

Tulmimetostat

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, VA Office of Research and Development, Washington University School of Medicine

Conditions

Advanced Solid TumorDiffuse Large B Cell LymphomaEndometrial CancerLymphoma, T-CellMesothelioma, MalignantMetastatic Castration-resistant Prostate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Mycosis Fungoides

Phase 1

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingNCT04104776
Novartis PharmaceuticalsAdvanced Solid Tumor, Diffuse Large B Cell Lymphoma, Endometrial Cancer +5
Start: 2019-09-18End: 2030-02-27Target: 300Updated: 2026-08-19
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
RecruitingNCT05467748
VA Office of Research and DevelopmentNon Small Cell Lung Cancer
Start: 2025-12-08End: 2029-12-07Target: 66Updated: 2026-01-27
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Active, not recruitingNCT05944562
Washington University School of MedicineMycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome
Start: 2024-01-09End: 2029-01-31Updated: 2026-09-16
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
RecruitingNCT07190300
Novartis PharmaceuticalsMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Start: 2026-01-13End: 2032-08-02Target: 181Updated: 2026-06-23

Related Papers

Combination of tulmimetostat and PD-1 blockade for patients with advanced non–small cell lung cancer who progressed from first or second line of treatments.
Journal of Clinical Oncology2026-05-28
Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with <i>ARID1A</i> -mutated ovarian clear cell carcinoma or endometrial carcinoma.
Journal of Clinical Oncology2025-05-28
Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies.
Journal of Clinical Oncology2024-06-011 citations
PR088/#198  EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)
2023-11-011 citations
EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results.
Journal of Clinical Oncology2023-06-0110 citations
Abstract 2126: Therapeutic potential of CPI-0209
Cancer Research2021-07-011 citations
Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.
Journal of Clinical Oncology2021-05-2016 citations